AVDL Earnings

AVDL reported its FY2025Q2 earnings on 2025-08-07, showcasing a revenue of 68.13M against an estimate of 60.28M, resulting in a 13.03% surprise. The EPS was 0.1, surpassing the expected 0.02 by 400%. The stock experienced a 14.77% price change on the earnings day and a 20.72% change over the next five days, reflecting market reactions to the results.

Following AVDL's FY2025Q2 earnings announcement on 2025-08-07, the stock price moved by 14.77% on the day of the release. Over the subsequent five days, it saw a 20.72% change. Historically, AVDL's stock price tends to shift by an average of -1.87% in the 10 days leading up to earnings and 7.5% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate AVDL's annual revenue to reach 80.30M, while the EPS is projected at 0.18. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AVDL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AVDL's stock price typically moves by -1.87% in the 10 days before its earnings and 7.5% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.18 and revenue of 80.30M.

The earnings call indicates strong financial performance with revenue growth and increased patient numbers. The guidance raise suggests confidence in continued growth, supported by sales force and reimbursement team expansions. Positive cash flow and a solid balance sheet further reinforce this outlook. Although some specifics were not disclosed in the Q&A, the overall sentiment remains positive, driven by strategic investments and market potential for LUMRYZ, especially in idiopathic hypersomnia. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.